Renovaro Biosciences Faces Key License Agreement Termination
Company Announcements

Renovaro Biosciences Faces Key License Agreement Termination

Renovaro Biosciences (RENB) has provided an update.

Renovaro Inc. has been notified about the termination of a crucial License Agreement with Weird Science LLC, which impacts their product candidate RENB-HV-01, a genetically modified cell therapy. Although this project was already deprioritized in favor of more promising ventures like the cancer vaccine candidate RENB-DC-11, the company hasn’t acknowledged the termination as final and is exploring its options. Despite this setback, Renovaro remains active in HIV research, working on innovative treatments to enhance the immune response against the virus.

For detailed information about RENB stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskRenovaro Biosciences Appoints Simon Tarsh as Interim CFO
TheFlyRenovaro BioSciences issues shareholder letter
TheFlyRenovaro BioSciences files $200M mixed securities shelf
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App